Health-related Quality of Life in GALAHAD: A Multicenter, Open-Label, Phase 2 Study of Niraparib for Patients with Metastatic Castration-Resistant Prostate Cancer and DNA-repair Gene Defects.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY（2023）
Key words
prostate cancer,niraparib,health-related,open-label,castration-resistant,dna-repair
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined